nnz-2566 & nnz-2591 fragile-x

It appears both compounds could offer a level of treatment for Fragile X ,


http://www.fraxa.org/new-treatment-strategy-emerges-igf-1/

"The surprising news is that FRAXA researchers have found that this treatment strategy works even better in Fragile X knockout mice than in Rett syndrome mice!"

http://www.neurenpharma.com/ssl/cms/files_cms/NNZ-2591%20Fragile%20X%20model.pdf

"Notably, this most recent study used a dose of NNZ-2591 approximately one-third that of NNZ-2566"


“We are truly excited with the outcome
of this study. These results in a well-accepted model of Fragile X Syndrome are compelling and
reinforce our belief that NNZ-2591 is a valuable compound with significant promise as a therapeutic
for chronic neurological conditions. That both NNZ-2566 and NNZ-2591 exhibit significant benefits in
this model suggests a “class effect” which has not previously been reported, in which two synthetic
analogues of naturally occurring neuropeptides show therapeutic potential in the same condition."